原発性骨粗鬆症におけるリセドロネートの治療成績

Outcomes of Risedronate in Patients with Osteoporosis

　女性の原発性骨粗鬆症（229例，平均71.0歳）におけるリセドロネートの治療効果を検討した．12例の新規骨折が発生し，そのうち5例は治療開始6カ月以内であった．腰椎骨密度は，12カ月後に平均5.3％増加し，尿NTXは，6カ月後には平均27.6％減少した．治療開始時に骨折リスクが高いと評価された症例の79.0％は6カ月以内に最小有意変化を示した．リセドロネートは新規骨折発生の抑制，腰椎骨密度の増加やNTXの抑制効果において優れた効果が認められ，骨粗鬆症治療の第一選択薬の1つとして有用であるといえた．

　To demonstrate the efficacy of oral risedronate in Japanese women with osteoporosis, we studied 229 patients 71.0 years of age. They were administered a daily oral dose of 2.5 mg of risedronate for at least 6 months. New fractures occurred in 12 cases (5 vertebral, 7 nonvertebral). Five of these were recognized within 6 months after treatment started. Bone mineral density at the lumbar spine increased 5.3％ during 12 months and urine NTX decreased 27.6％ at 6 months. The positive predictive value indicated that at a probability of 83.3％, bone mineral density would increase above 2％ at 12 months if urinary NTX decreased below 35％ at 6 months. Risedronate was thus effective in Japanese women with osteoporosis.